Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -3.45M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -154.07M | $ -143.72M | $ -145.60M | $ -130.71M | $ -63.47M |
| EBITDA | $ -134.75M | $ -141.57M | $ -143.45M | $ -128.57M | $ -62.80M |
| Net Income | $ -138.20M | $ -134.24M | $ -141.95M | $ -130.32M | $ -63.41M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 312.02M | $ 259.72M | $ 242.66M | $ 242.72M | $ 351.21M |
| Total Assets | $ 350.07M | $ 297.67M | $ 285.10M | $ 287.04M | $ 355.95M |
| Total Debt | $ 28.97M | $ 31.36M | $ 32.86M | $ 34.59M | $ 0.00 |
| Net Debt | $ -20.53M | $ -193.75M | $ -107.16M | $ -40.25M | $ -268.56M |
| Total Liabilities | $ 56.97M | $ 47.12M | $ 53.90M | $ 55.13M | $ 11.67M |
| Stockholders' Equity | $ 293.11M | $ 250.56M | $ 231.19M | $ 231.91M | $ 344.28M |
| Cash Flow | |||||
| Free Cash Flow | $ -118.02M | $ -121.33M | $ -122.83M | $ -107.76M | $ -53.55M |
| Operating Cash Flow | $ -118.01M | $ -121.14M | $ -116.31M | $ -106.11M | $ -53.09M |
| Investing Cash Flow | $ -218.80M | $ 70.70M | $ 58.44M | $ -88.24M | $ -83.16M |
| Financing Cash Flow | $ 161.21M | $ 135.52M | $ 122.91M | $ 1.79M | $ 360.88M |